Shetty N, Wilson A P
Department of Clinical Microbiology, University College London Hospitals, Grafton Way, London WC1E 6DB, UK.
J Antimicrob Chemother. 2000 Oct;46(4):633-8. doi: 10.1093/jac/46.4.633.
Sitafloxacin is a new quinolone active against multi-resistant Gram-positive pathogens. An open study was conducted in patients with serious systemic infections with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant enterococcus (VRE). Patients with MRSA were recruited if treatment with glycopeptides had failed. Of 11 patients with MRSA infection, four were cured, six failed treatment and one was indeterminate. Of nine patients with VRE infection (one patient had both pathogens), five were cured and four failed. Fifteen adverse events in 12 patients were potentially related to the study drug. Sitafloxacin was effective in VRE and some recalcitrant MRSA infections.
西他沙星是一种新型喹诺酮类药物，对多重耐药革兰氏阳性病原体具有活性。对患有耐甲氧西林金黄色葡萄球菌（MRSA）或耐万古霉素肠球菌（VRE）引起的严重全身感染的患者进行了一项开放性研究。如果糖肽类药物治疗失败，则招募患有MRSA的患者。在11例MRSA感染患者中，4例治愈，6例治疗失败，1例结果不确定。在9例VRE感染患者中（1例患者同时感染两种病原体），5例治愈，4例治疗失败。12例患者出现的15起不良事件可能与研究药物有关。西他沙星对VRE和一些顽固性MRSA感染有效。
